Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied

Background. Human papillomavirus (HPV) vaccination of girls with very high (>90%) coverage has the potential to eradicate oncogenic HPVs, but such high coverage is hard to achieve. However, the herd effect (HE) depends both on the HPV type and the vaccination strategy. Methods. We randomized 33 F...

ver descrição completa

Detalhes bibliográficos
Autores: Vänskä, Simopekka, Luostarinen, Tapio, Baussano, Iacopo, Apter, Dan, Eriksson, Tiina, Natunen, Kari, Nieminen, Pekka, Paavonen, Jorma, Pimenoff, Ville Nikolai, Pukkala, Eero, Söderlund-Strand, Anna, Dubin, Gary O., Garnett, Geoff, Dillner, Joakim, Lehtinen, Matti
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/173415
Acesso em linha:https://hdl.handle.net/2445/173415
Access Level:acceso abierto
Palavra-chave:Papil·lomavirus
Vacunes antivíriques
Papillomaviruses
Viral vaccines
id ES_ed2dea4df60ce55efe806ada73b703da
oai_identifier_str oai:recercat.cat:2445/173415
network_acronym_str ES
network_name_str España
repository_id_str
spelling Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is AppliedVänskä, SimopekkaLuostarinen, TapioBaussano, IacopoApter, DanEriksson, TiinaNatunen, KariNieminen, PekkaPaavonen, JormaPimenoff, Ville NikolaiPukkala, EeroSöderlund-Strand, AnnaDubin, Gary O.Garnett, GeoffDillner, JoakimLehtinen, MattiPapil·lomavirusVacunes antivíriquesPapillomavirusesViral vaccinesBackground. Human papillomavirus (HPV) vaccination of girls with very high (>90%) coverage has the potential to eradicate oncogenic HPVs, but such high coverage is hard to achieve. However, the herd effect (HE) depends both on the HPV type and the vaccination strategy. Methods. We randomized 33 Finnish communities into gender-neutral HPV16/18 vaccination, girls-only HPV16/18 vaccination, and hepatitis B virus vaccination arms. In 2007-2010, 11 662 of 20 513 of 40 852 of 39 420 resident boys/girls from 1992 to 1995 birth cohorts consented. In 2010-2014, cervicovaginal samples from vaccinated and unvaccinated girls at age 18.5 years were typed for HPV6/11/16/18/31/33/35/39/45/51/52/56/58/59/66/68. Vaccine efficacy for vaccinated girls, HE for unvaccinated girls, and the protective effectiveness (PE) for all girls were estimated. We extended the community-randomized trial results about vaccination strategy with mathematical modeling to assess HPV eradication. Results. The HE and PE estimates in the 1995 birth cohort for HPV18/31/33 were significant in the gender-neutral arm and 150% and 40% stronger than in the girls-only arm. Concordantly, HPV18/31/33 eradication was already predicted in adolescents/young adults in 20 years with 75% coverage of gender-neutral vaccination. With the 75% coverage, eventual HPV16 eradication was also predicted, but only with the gender-neutral strategy. Conclusions. Gender-neutral vaccination is superior for eradication of oncogenic HPVs.Oxford University Press Inc.2021202120202021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion9 p.application/pdfhttps://hdl.handle.net/2445/173415Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.1093/infdis/jiaa099Journal of Infectious Diseases, 2020, vol. 222, num. 6, p. 948-956https://doi.org/10.1093/infdis/jiaa099cc by-nc-nd (c) Vänskä et al., 2020http://creativecommons.org/licenses/by-nc-nd/3.0/es/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/1734152026-05-29T05:05:01Z
dc.title.none.fl_str_mv Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied
title Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied
spellingShingle Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied
Vänskä, Simopekka
Papil·lomavirus
Vacunes antivíriques
Papillomaviruses
Viral vaccines
title_short Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied
title_full Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied
title_fullStr Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied
title_full_unstemmed Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied
title_sort Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied
dc.creator.none.fl_str_mv Vänskä, Simopekka
Luostarinen, Tapio
Baussano, Iacopo
Apter, Dan
Eriksson, Tiina
Natunen, Kari
Nieminen, Pekka
Paavonen, Jorma
Pimenoff, Ville Nikolai
Pukkala, Eero
Söderlund-Strand, Anna
Dubin, Gary O.
Garnett, Geoff
Dillner, Joakim
Lehtinen, Matti
author Vänskä, Simopekka
author_facet Vänskä, Simopekka
Luostarinen, Tapio
Baussano, Iacopo
Apter, Dan
Eriksson, Tiina
Natunen, Kari
Nieminen, Pekka
Paavonen, Jorma
Pimenoff, Ville Nikolai
Pukkala, Eero
Söderlund-Strand, Anna
Dubin, Gary O.
Garnett, Geoff
Dillner, Joakim
Lehtinen, Matti
author_role author
author2 Luostarinen, Tapio
Baussano, Iacopo
Apter, Dan
Eriksson, Tiina
Natunen, Kari
Nieminen, Pekka
Paavonen, Jorma
Pimenoff, Ville Nikolai
Pukkala, Eero
Söderlund-Strand, Anna
Dubin, Gary O.
Garnett, Geoff
Dillner, Joakim
Lehtinen, Matti
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Papil·lomavirus
Vacunes antivíriques
Papillomaviruses
Viral vaccines
topic Papil·lomavirus
Vacunes antivíriques
Papillomaviruses
Viral vaccines
description Background. Human papillomavirus (HPV) vaccination of girls with very high (>90%) coverage has the potential to eradicate oncogenic HPVs, but such high coverage is hard to achieve. However, the herd effect (HE) depends both on the HPV type and the vaccination strategy. Methods. We randomized 33 Finnish communities into gender-neutral HPV16/18 vaccination, girls-only HPV16/18 vaccination, and hepatitis B virus vaccination arms. In 2007-2010, 11 662 of 20 513 of 40 852 of 39 420 resident boys/girls from 1992 to 1995 birth cohorts consented. In 2010-2014, cervicovaginal samples from vaccinated and unvaccinated girls at age 18.5 years were typed for HPV6/11/16/18/31/33/35/39/45/51/52/56/58/59/66/68. Vaccine efficacy for vaccinated girls, HE for unvaccinated girls, and the protective effectiveness (PE) for all girls were estimated. We extended the community-randomized trial results about vaccination strategy with mathematical modeling to assess HPV eradication. Results. The HE and PE estimates in the 1995 birth cohort for HPV18/31/33 were significant in the gender-neutral arm and 150% and 40% stronger than in the girls-only arm. Concordantly, HPV18/31/33 eradication was already predicted in adolescents/young adults in 20 years with 75% coverage of gender-neutral vaccination. With the 75% coverage, eventual HPV16 eradication was also predicted, but only with the gender-neutral strategy. Conclusions. Gender-neutral vaccination is superior for eradication of oncogenic HPVs.
publishDate 2020
dc.date.none.fl_str_mv 2020
2021
2021
2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/173415
url https://hdl.handle.net/2445/173415
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1093/infdis/jiaa099
Journal of Infectious Diseases, 2020, vol. 222, num. 6, p. 948-956
https://doi.org/10.1093/infdis/jiaa099
dc.rights.none.fl_str_mv cc by-nc-nd (c) Vänskä et al., 2020
http://creativecommons.org/licenses/by-nc-nd/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by-nc-nd (c) Vänskä et al., 2020
http://creativecommons.org/licenses/by-nc-nd/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 9 p.
application/pdf
dc.publisher.none.fl_str_mv Oxford University Press Inc.
publisher.none.fl_str_mv Oxford University Press Inc.
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423431353630720
score 15,811543

Registos relacionados